Jacobson Pharma expects significant profit surge in FY2025

Jacobson Pharma Corporation Limited announced it expects a profit increase of over 40% from continuing operations for the fiscal year ending March 31, 2025 (FY2025), compared to the previous year. This positive outlook is attributed to the strong performance of both specialty medicines and the overall generic drug business, further boosted by revenue contributions from new product launches and in-licensing agreements. The company also cited increased operating leverage and effective cost control measures as contributing factors. Furthermore, following the distribution of JBM Healthcare shares as a special dividend in August 2023, the profit attributable to equity shareholders for FY2025 is expected to rise by over 10% compared to FY2024. The company plans to release its annual results announcement for FY2025 on June 13, 2025.